Last reviewed · How we verify
Autologous Tumor Infiltrating Lymphocytes
At a glance
| Generic name | Autologous Tumor Infiltrating Lymphocytes |
|---|---|
| Also known as | GC101 TIL injection |
| Sponsor | Vastra Gotaland Region |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of OBX-115 in Advanced Solid Tumors (PHASE1, PHASE2)
- Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma (PHASE2)
- T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer (PHASE2)
- Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer (PHASE2)
- LM103 in Phase IIa Clinical Trial for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer (PHASE2)
- A Phase II Trial of LM103 in Advanced Melanoma (PHASE2)
- Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors (PHASE1)
- ACT-TIL and ANV419 for Advanced Melanoma. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: